NR1H4 and metabolic dysfunction-associated steatohepatitis: The FXR agonist EDP-305 may be more relevant for mitigating the progression of PBC as it has been shown to reduce interstitial renal fibrosis and hepatic fibrosis in NASH.26,27 However, a previous clinical trial in PBC patients, the INTREPID trial (NCT03394924), failed to meet the primary endpoint of a 20% reduction in the alkaline phosphatase.